United Interest Income from 2010 to 2026

UTHR Stock

USD 488.91 14.78 2.93%

United Therapeutics Interest Income yearly trend continues to be relatively stable with very little volatility. Interest Income is likely to grow to about 240.4 M this year. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

51.3 M

Current Value

46.4 M

Quarterly Volatility

19.9 M

Covid

Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.5 M, Total Revenue of 3.5 B or Gross Profit of 3.1 B, as well as many indicators such as Price To Sales Ratio of 6.06, Dividend Yield of 0.0114 or PTB Ratio of 4.07. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.

Build AI portfolio with United Stock

Check out the analysis of United Therapeutics Correlation against competitors.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

Latest United Therapeutics' Interest Income Growth Pattern

Below is the plot of the Interest Income of United Therapeutics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. United Therapeutics' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

United Interest Income Regression Statistics

	Arithmetic Mean	60,928,721
	Geometric Mean	20,457,303
	Coefficient Of Variation	141.76
	Mean Deviation	69,113,337
	Median	16,700,000
	Standard Deviation	86,374,392
	Sample Variance	7460.5T
	Range	236.5M
	R-Value	0.82
	Mean Square Error	2661.4T
	R-Squared	0.67
	Significance	0.000065
	Slope	13,954,426
	Total Sum of Squares	119368.6T

United Interest Income History

	2026	240.4 M
	2025	229 M
	2024	199.1 M
	2023	162.7 M
	2022	45.2 M
	2021	16.7 M

Other Fundumenentals of United Therapeutics

Net Interest Income

United Therapeutics Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Good Will	Short Term Investments	Short Term Debt	Intangible Assets	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.6	0.98	-0.24	0.82	0.61	0.99	0.93	0.95	0.68	0.54	0.54	0.44	-0.67	0.94	0.42	0.99	0.82	0.81	0.92	0.7	0.92	0.91	-0.86
Total Stockholder Equity	1.0		-0.65	0.99	-0.23	0.83	0.55	0.99	0.91	0.94	0.64	0.53	0.51	0.38	-0.64	0.92	0.39	0.98	0.79	0.79	0.91	0.67	0.92	0.91	-0.83
Net Debt	-0.6	-0.65		-0.69	0.19	-0.76	0.04	-0.66	-0.43	-0.4	-0.04	-0.23	-0.41	0.29	0.45	-0.5	-0.17	-0.56	-0.31	-0.52	-0.33	-0.13	-0.51	-0.51	0.24
Retained Earnings	0.98	0.99	-0.69		-0.27	0.85	0.53	0.99	0.92	0.91	0.6	0.58	0.51	0.38	-0.71	0.92	0.3	0.98	0.78	0.82	0.87	0.68	0.9	0.88	-0.81
Accounts Payable	-0.24	-0.23	0.19	-0.27		-0.23	-0.23	-0.26	-0.17	-0.24	0.01	0.02	0.01	-0.11	0.31	-0.18	0.12	-0.3	-0.25	-0.37	-0.26	-0.29	-0.28	-0.27	0.34
Net Receivables	0.82	0.83	-0.76	0.85	-0.23		0.46	0.84	0.7	0.66	0.5	0.37	0.66	0.15	-0.74	0.83	0.35	0.78	0.57	0.76	0.65	0.5	0.66	0.65	-0.52
Total Liab	0.61	0.55	0.04	0.53	-0.23	0.46		0.57	0.66	0.65	0.74	0.4	0.69	0.79	-0.67	0.73	0.39	0.61	0.82	0.74	0.69	0.77	0.64	0.62	-0.77
Total Current Assets	0.99	0.99	-0.66	0.99	-0.26	0.84	0.57		0.91	0.94	0.63	0.52	0.53	0.39	-0.68	0.93	0.39	0.98	0.79	0.82	0.88	0.67	0.91	0.91	-0.83
Good Will	0.93	0.91	-0.43	0.92	-0.17	0.7	0.66	0.91		0.91	0.69	0.75	0.53	0.56	-0.74	0.94	0.27	0.93	0.8	0.81	0.87	0.75	0.84	0.83	-0.85
Short Term Investments	0.95	0.94	-0.4	0.91	-0.24	0.66	0.65	0.94	0.91		0.72	0.5	0.42	0.54	-0.57	0.89	0.41	0.96	0.82	0.75	0.94	0.74	0.93	0.94	-0.88
Short Term Debt	0.68	0.64	-0.04	0.6	0.01	0.5	0.74	0.63	0.69	0.72		0.36	0.51	0.69	-0.49	0.74	0.43	0.68	0.64	0.51	0.77	0.81	0.62	0.61	-0.68
Intangible Assets	0.54	0.53	-0.23	0.58	0.02	0.37	0.4	0.52	0.75	0.5	0.36		0.37	0.36	-0.62	0.61	-0.07	0.51	0.5	0.55	0.44	0.47	0.45	0.4	-0.53
Common Stock	0.54	0.51	-0.41	0.51	0.01	0.66	0.69	0.53	0.53	0.42	0.51	0.37		0.33	-0.65	0.69	0.49	0.47	0.57	0.71	0.39	0.43	0.51	0.51	-0.39
Long Term Debt	0.44	0.38	0.29	0.38	-0.11	0.15	0.79	0.39	0.56	0.54	0.69	0.36	0.33		-0.52	0.53	0.15	0.51	0.72	0.52	0.6	0.76	0.46	0.48	-0.73
Treasury Stock	-0.67	-0.64	0.45	-0.71	0.31	-0.74	-0.67	-0.68	-0.74	-0.57	-0.49	-0.62	-0.65	-0.52		-0.77	0.0	-0.69	-0.72	-0.89	-0.55	-0.72	-0.56	-0.55	0.63
Property Plant Equipment	0.94	0.92	-0.5	0.92	-0.18	0.83	0.73	0.93	0.94	0.89	0.74	0.61	0.69	0.53	-0.77		0.47	0.92	0.79	0.84	0.84	0.7	0.81	0.8	-0.81
Current Deferred Revenue	0.42	0.39	-0.17	0.3	0.12	0.35	0.39	0.39	0.27	0.41	0.43	-0.07	0.49	0.15	0.0	0.47		0.33	0.27	0.19	0.4	0.04	0.34	0.34	-0.28
Net Tangible Assets	0.99	0.98	-0.56	0.98	-0.3	0.78	0.61	0.98	0.93	0.96	0.68	0.51	0.47	0.51	-0.69	0.92	0.33		0.84	0.82	0.93	0.76	0.93	0.93	-0.88
Long Term Debt Total	0.82	0.79	-0.31	0.78	-0.25	0.57	0.82	0.79	0.8	0.82	0.64	0.5	0.57	0.72	-0.72	0.79	0.27	0.84		0.89	0.84	0.84	0.88	0.86	-0.92
Capital Surpluse	0.81	0.79	-0.52	0.82	-0.37	0.76	0.74	0.82	0.81	0.75	0.51	0.55	0.71	0.52	-0.89	0.84	0.19	0.82	0.89		0.7	0.76	0.81	0.8	-0.76
Long Term Investments	0.92	0.91	-0.33	0.87	-0.26	0.65	0.69	0.88	0.87	0.94	0.77	0.44	0.39	0.6	-0.55	0.84	0.4	0.93	0.84	0.7		0.79	0.91	0.87	-0.91
Short Long Term Debt	0.7	0.67	-0.13	0.68	-0.29	0.5	0.77	0.67	0.75	0.74	0.81	0.47	0.43	0.76	-0.72	0.7	0.04	0.76	0.84	0.76	0.79		0.74	0.73	-0.8
Net Invested Capital	0.92	0.92	-0.51	0.9	-0.28	0.66	0.64	0.91	0.84	0.93	0.62	0.45	0.51	0.46	-0.56	0.81	0.34	0.93	0.88	0.81	0.91	0.74		0.98	-0.86
Net Working Capital	0.91	0.91	-0.51	0.88	-0.27	0.65	0.62	0.91	0.83	0.94	0.61	0.4	0.51	0.48	-0.55	0.8	0.34	0.93	0.86	0.8	0.87	0.73	0.98		-0.83
Capital Stock	-0.86	-0.83	0.24	-0.81	0.34	-0.52	-0.77	-0.83	-0.85	-0.88	-0.68	-0.53	-0.39	-0.73	0.63	-0.81	-0.28	-0.88	-0.92	-0.76	-0.91	-0.8	-0.86	-0.83

Click cells to compare fundamentals

About United Therapeutics Financial Statements

United Therapeutics shareholders use historical fundamental indicators, such as Interest Income, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in United Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on United Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Interest Income	229 M	240.4 M
Net Interest Income	179.6 M	188.6 M

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.77

AMGN

Amgen Inc

Pair Corr

Moving against United Stock

0.83	MSFT	Microsoft	Pair Corr
0.82	HPQ	HP Inc	Pair Corr
0.82	HD	Home Depot Sell-off Trend	Pair Corr
0.7	PG	Procter Gamble	Pair Corr
0.33	DOCKF	Beyond Medical Techn	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

United Interest Income from 2010 to 2026

Latest United Therapeutics' Interest Income Growth Pattern

United Interest Income Regression Statistics

United Interest Income History

Other Fundumenentals of United Therapeutics

United Therapeutics Interest Income component correlations

About United Therapeutics Financial Statements

Pair Trading with United Therapeutics

Moving together with United Stock

Moving against United Stock

Additional Tools for United Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY